

Recall Notification

PharmPix Clinical Department

PharmPix is committed to the health and wellness of our members. The clinical team wants to communicate the latest up-to-date drug recall.

Levothyroxine Tablets Recalled Due to Potency Issue

**U.S. Food & Drug Administration
Publication Date:**

07/13/2026

National Drug Code:

Refer to notification

Product Description:

The medicine replaces thyroid hormone when the body cannot produce enough.

Batch (Lot) Number:

Refer to notification

Expiration Date:

Refer to notification

Company:

Major Pharmaceuticals

Questions:

Call Sedgwick, Inc. at 1-800-386-4756, Monday through Friday from 8:00 AM to 5:00 PM EST.

It is for this reason that we are notifying you that on July 13, 2026, the U.S. Food and Drug Administration (FDA) published a drug recall for the following products: Levothyroxine sodium tablets.

Reason for Recall

Major Pharmaceuticals has announced a nationwide recall of multiple lots of levothyroxine sodium tablets, a prescription medication used to treat thyroid disorders, after testing found that some tablets may contain less active ingredient than labeled. The recall includes several strengths of levothyroxine sodium tablets ranging from 25 mcg to 150 mcg, with expiration dates from July 2026 through January 2027. Products distributed by Major Pharmaceuticals were packaged in 100-tablet cartons containing ten 10-tablet unit-dose blister packs (10 × 10 configuration). In addition, certain recalled lots were distributed by Cardinal Health and packaged in 10-tablet cartons containing ten 1-tablet unit-dose blister packs (10 × 1 configuration). All affected products are prescription-only levothyroxine sodium tablets.

Pharmacy Required Action

Identify if the product is in inventory and immediately stop using and dispensing it. The product should be returned to the place of purchase or as directed in the recall notification.

Advise patients experiencing any problem while taking or using this product to contact their physician.

Description of product(s) recalled:

Product Name	Dosage Strength	NDC	Lot Number	Expiration Date
Levothyroxine sodium tablets	25 mcg	0904-6949-61	N02212	July 2026
	50 mcg	0904-6950-61	N02200	October 2026
	75 mcg	0904-6951-61	N02172, N02288, N02296	July - December 2026
	88 mcg	0904-6952-61	N02310	January 2027
	112 mcg	0904-6954-61	N02203	September 2026
	125 mcg	0904-6955-61	N02266	November 2026
	150 mcg tablet blister packs	0904-6956-61	N02167	July 2026

Remember you can report adverse events related to this or any other drug product at [MedWatch: The FDA Safety Information and Adverse Event Reporting Program](#) by any of the following ways:

Complete and submit the [MedWatch Online Voluntary Reporting Form](#) online.

[Download](#) FDA Form 3500 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

Additional information can be found at: [MedWatch: The FDA Safety Information and Adverse Event Reporting Program](#).

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you.

In addition, know that you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

REFERENCES:

1. Passion Health Physicians. (2026). *Levothyroxine recall 2026*. <https://passionhealthphysicians.com/levothyroxine-recall-2026/>
2. The Hill. (2026). *Thyroid medicine recalled nationwide: FDA*. <https://thehill.com/homenews/5993192-thyroid-medicine-recalled-nationwide-fda/>
3. U.S. Food and Drug Administration. (2026). *FDA recall event 99399*. <https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99399>
4. Major Pharmaceuticals. (2026, July 14). *Levothyroxine sodium tablets market recall: Customer notification and response form*. Scribd. <https://www.scribd.com/document/1066758405/Levothyroxine-Sodium-Tablets-Market-Recall-Customer-Notification-and-Response-Form-07-14-2026>
5. AARP. (2026). *Levothyroxine thyroid medication recall (July 2026)*. <https://www.aarp.org/health/conditions-treatments/evothyroxine-thyroid-medication-recall-july-2026/>